肉瘤中FGFR信号通路研究进展  

Update of fibroblast growth factor receptor signaling pathway in sarcoma

作　　者：周文雅[1] 王国文[1] 杨蕴[1] 杨吉龙[1] 

机构地区：[1]天津医科大学附属肿瘤医院骨与软组织肿瘤科国家肿瘤临床研究中心天津市肿瘤防治重点实验室,300060

出　　处：《中国骨与关节杂志》2015年第9期720-724,共5页Chinese Journal of Bone and Joint

基　　金：国家自然科学基金(81372872;81402215)

摘　　要：肉瘤是来自于神经、肌肉、脂肪和骨骼等间叶组织的少见的恶性肿瘤,它可以发生于全身各处,尤其好发于肢体深部组织。在成人恶性肿瘤中肉瘤只占1%,而在儿童肿瘤中占21%[1]。在肉瘤中,软组织肉瘤占肉瘤的大部分,原发恶性骨肿瘤只占10%左右[2]。由于这种疾病发病率低,亚型繁多,加上疾病进展迅速和病灶易复发转移而导致预后不良。Sarcomas are derived from mesenchymal tissues, with poor outcomes of traditional treatment such as surgery, chemotherapy, and radiotherapy. Hence, new treatment methods such like target therapy in human cancer are very necessary. Fibroblast growth factor receptor （ FGFR ） signaling pathway plays a ubiquitous role in a variety of biological processes including regulating normal cell growth, proliferation, differentiation, and angiogenesis, but has also associated with a variety of dysplasia syndromes and cancers. The therapies and related drugs which target at FGFR signaling pathway have made great progress in the field of tumors. An overview of the role of FGF / FGFR pathway signal and their inhibitors in sarcoma which might be new targets for the treatment of sarcomas according to the recent research will be presented.

关 键 词：肉瘤 成纤维细胞生长因子 成纤维细胞生长因子受体 信号传导 分子靶向治疗 

分 类 号：R738.1[医药卫生—肿瘤]